Spotlight on Allergy & Immunology
Airway Hyperresponsiveness
StartActivity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
Activity Description
This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Activity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
Activity Description
This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Allergy & Immunology Presentations
Airway Hyperresponsiveness
StartActivity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
Activity Description
This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Activity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
Activity Description
This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Monograph
StartActivity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
- Discuss the implications of AHR for treatment selection in severe asthma
- Compare the effects of current and emerging biologic therapies on AHR in clinical studies
Activity Description
This activity presents the content from videos 1 and 2 in a text-based monograph as an alternative format. The activity is focused on airway hyperresponsiveness, its clinical significance, and emerging treatments. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Esther Langmack, MD, has no relevant financial relationships
to disclose.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test with a minimum score of 3 out of 4
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Activity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
- Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
- Discuss the implications of AHR for treatment selection in severe asthma
- Compare the effects of current and emerging biologic therapies on AHR in clinical studies
Activity Description
This activity presents the content from videos 1 and 2 in a text-based monograph as an alternative format. The activity is focused on airway hyperresponsiveness, its clinical significance, and emerging treatments. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Esther Langmack, MD, has no relevant financial relationships
to disclose.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test with a minimum score of 3 out of 4
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Clinical Significance of Airway Hyperresponsiveness
StartActivity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Discuss the implications of AHR for treatment selection in severe asthma
- Compare the effects of current and emerging biologic therapies on AHR in clinical studies
Activity Description
This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Activity Details
Expires: May 27, 2023
Accredited By
National Jewish Health
Target Audience
Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.
Learning Objectives
- Discuss the implications of AHR for treatment selection in severe asthma
- Compare the effects of current and emerging biologic therapies on AHR in clinical studies
Activity Description
This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.
Statement of Educational Need
Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.
Faculty
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships
to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant
financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a
speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board
for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships
to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK
and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships
to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant
for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi
Regeneron. He is also an investigator for AstraZeneca and
GlaxoSmithKline.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- View the online activity.
- Complete the post-test with a minimum score of 1 out of 2
- Submit the evaluation form.
Certificates will be emailed to the participant.
Statement of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect
personal information that you voluntarily share with us. We will only use
this information to notify you of future National Jewish Health CME
activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Contact Information for Questions About the Activity
For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.
Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria
StartActivity Details
0.25 ABIM MOC Point(s)
Expires: April 18, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.
Faculty
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ABIM MOC Point(s)
Expires: April 18, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.
Faculty
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19
StartActivity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
HIV PrEP: Strategies for Risk Reduction and Improved Adherence
StartActivity Details
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Expires: March 14, 2023
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
- Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
- Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.
Activity Description
HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.
Statement of Educational Need
Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.
Agenda
Introduction - David A. Wohl, MD
Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH
PrEP Therapies and Adherence Strategies - David A. Wohl, MD
Case Presentation & Panel Discussion - All Faculty
Activity Chair
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV
Faculty
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL
Disclosure: No relevant financial relationships to disclose.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Vindico Medical Education is accredited
by the Accreditation Council for Pharmacy Education (ACPE) as a provider of
continuing pharmacy education.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity enables the participant to earn up to 1.0 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.
Statement of Commercial Support
This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Expires: March 14, 2023
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
- Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
- Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.
Activity Description
HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.
Statement of Educational Need
Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.
Agenda
Introduction - David A. Wohl, MD
Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH
PrEP Therapies and Adherence Strategies - David A. Wohl, MD
Case Presentation & Panel Discussion - All Faculty
Activity Chair
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV
Faculty
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL
Disclosure: No relevant financial relationships to disclose.
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Vindico Medical Education is accredited
by the Accreditation Council for Pharmacy Education (ACPE) as a provider of
continuing pharmacy education.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME
activity enables the participant to earn up to 1.0 Medical Knowledge MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility
to submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.
Statement of Commercial Support
This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Challenging Cases: BCC in HIV Infection, New Skin Lesions in Metastatic CSCC
StartActivity Details
0.25 ANCC contact hour(s)
0.25 ABIM MOC Point(s)
Expires: February 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
- Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data
Activity Description
As immunotherapy is integrated into the treatment armamentarium for advanced nonmelanoma skin cancer, clinicians may be challenged by unique situations such as comorbid HIV or the development of new primary lesions. In this program, experts provide privileged insights into real-world cases submitted by dermatologists and oncologists.
Co-Chairs
Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Karl D. Lewis, MD, has relevant financial relationships with Merck, Pfizer, Regeneron, Roche, Sanofi (Consultant); BMS, Genentech, Incyte, Iovance, Kartos, Merck, Nektar Therapeutics, OncoSec, Pfizer/Array, Regeneron, Replimune, Seattle Genetics, Senhwa, Ultimovacs (Grant/Research Support).
Ahmad Tarhini, MD, PhD, has relevant financial relationships with Bristol Myers Squibb, Clinigen, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Regeneron, Sanofi Genzyme (Consultant); Bristol Myers Squibb, Clinigen, Genentech-Roche, Navigate, Nektar Therapeutics, OncoSec, Regeneron, Sanofi Genzyme (Researcher).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC contact hour(s)
0.25 ABIM MOC Point(s)
Expires: February 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
- Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data
Activity Description
As immunotherapy is integrated into the treatment armamentarium for advanced nonmelanoma skin cancer, clinicians may be challenged by unique situations such as comorbid HIV or the development of new primary lesions. In this program, experts provide privileged insights into real-world cases submitted by dermatologists and oncologists.
Co-Chairs
Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Karl D. Lewis, MD, has relevant financial relationships with Merck, Pfizer, Regeneron, Roche, Sanofi (Consultant); BMS, Genentech, Incyte, Iovance, Kartos, Merck, Nektar Therapeutics, OncoSec, Pfizer/Array, Regeneron, Replimune, Seattle Genetics, Senhwa, Ultimovacs (Grant/Research Support).
Ahmad Tarhini, MD, PhD, has relevant financial relationships with Bristol Myers Squibb, Clinigen, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Regeneron, Sanofi Genzyme (Consultant); Bristol Myers Squibb, Clinigen, Genentech-Roche, Navigate, Nektar Therapeutics, OncoSec, Regeneron, Sanofi Genzyme (Researcher).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.